Edition:
India

Synlogic Inc (SYBX.OQ)

SYBX.OQ on NASDAQ Stock Exchange Global Market

9.40USD
1:30am IST
Change (% chg)

$-0.15 (-1.57%)
Prev Close
$9.55
Open
$9.51
Day's High
$9.55
Day's Low
$9.24
Volume
32,987
Avg. Vol
23,457
52-wk High
$23.00
52-wk Low
$8.73

Latest Key Developments (Source: Significant Developments)

Synlogic Q1 Loss Per Share $0.55
Tuesday, 15 May 2018 

May 15 (Reuters) - Synlogic Inc ::SYNLOGIC REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.55.Q1 EARNINGS PER SHARE VIEW $-0.73 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, SYNLOGIC HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $125.8 MILLION.  Full Article

Synlogic Agrees To Sell 3.3 Mln Shares To Mutual Fund Investor In Registered Direct Offering​​
Friday, 6 Apr 2018 

April 6 (Reuters) - Synlogic Inc ::SYNLOGIC ANNOUNCES REGISTERED DIRECT OFFERING OF COMMON STOCK.SYNLOGIC INC - ‍ANTICIPATES AGGREGATE GROSS PROCEEDS FROM OFFERING WILL BE APPROXIMATELY $30.0 MLN BASED ON OFFERING PRICE OF $9.15 PER SHARE​​.SYNLOGIC INC - ‍IT HAS AGREED TO SELL 3.3 MLN SHARES OF ITS COMMON STOCK TO A LARGE MUTUAL FUND INVESTOR IN A REGISTERED DIRECT OFFERING​​.SYNLOGIC INC - ‍ INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ITS TWO PLANNED PHASE 1B/2A CLINICAL TRIALS OF THROUGH COMPLETION​​.SYNLOGIC INC - ALSO ‍ INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND ITS PLANNED PHASE 1/2A CLINICAL TRIAL OF SYNB1618 THROUGH COMPLETION​​.  Full Article

Synlogic Progresses Clinical And Preclinical Pipeline And Outlines 2018 Catalysts
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Synlogic Inc ::SYNLOGIC PROGRESSES CLINICAL AND PRECLINICAL PIPELINE AND OUTLINES 2018 CATALYSTS.SYNLOGIC - EXPECTS TO PRESENT FULL CLINICAL DATA FROM FIRST IN-HUMAN STUDY OF SYNTHETIC BIOTIC MEDICINE EXPECTED IN Q1 2018.SYNLOGIC INC - IND FOR SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH LIVER DISEASE HAS BEEN CLEARED BY FDA.SYNLOGIC INC - ADDITIONAL TRIALS IN PATIENTS WITH UCD AND PKU EXPECTED TO BEGIN IN 2018.  Full Article

Synlogic, Ginkgo Bioworks To Collaborate To Discover New Living Medicines To Treat Neurological And Liver Disorders
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Synlogic Inc ::SYNLOGIC INC - CO, ORGANISM COMPANY GINKGO BIOWORKS TO COLLABORATE TO DISCOVER NEW LIVING MEDICINES TO TREAT NEUROLOGICAL AND LIVER DISORDERS.  Full Article

Synlogic qtrly loss per share $1.66‍​
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Synlogic Inc ::Synlogic reports third quarter 2017 financial results and recent progress.Q3 revenue $100,000.Synlogic Inc - qtrly loss per share $1.66‍​.  Full Article

Synlogic says ‍SYNB1020 was safe, well tolerated in subjects
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Synlogic Inc :Synlogic reports positive top-line phase 1 data demonstrating safety and tolerability and proof of mechanism in healthy volunteers for synb1020, a synthetic biotictm medicine for the treatment of hyperammonemia.Synlogic inc - ‍data support initiation of two phase 1b/2a studies in 2018​.Synlogic - ‍synb1020 was safe, well tolerated in subjects in multiple ascending dose cohorts.Synlogic - ‍there have been no serious adverse events, no cases of infection with bacteria in synb1020 study ​.  Full Article

Synlogic says co entered into sales agreement with Cowen And Company, LLC ​
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Synlogic Inc :Synlogic Inc - ‍on October 13, 2017 co entered into a sales agreement with Cowen And Company, LLC - SEC filing ​.Synlogic Inc - pursuant to agreement co may offer and sell, shares of its common stock, par value $0.001 per share having an offering price of up to $50 million.  Full Article

Mirna therapeutics' investigational new drug for MRX34 has been placed on full clinical hold
Friday, 30 Sep 2016 

Mirna Therapeutics Inc : Investigational new drug for MRX34, investigational Microrna Therapy for multiple cancers, has been placed on full clinical hold .Anticipates that it will receive a formal clinical hold letter from FDA within 30 days - SEC filing.  Full Article

Mirna Therapeutics qtrly net loss attributable to common stockholders $5.64 mln
Monday, 15 Aug 2016 

Mirna Therapeutics Inc : Mirna therapeutics reports second quarter 2016 financial results and program updates . Qtrly net loss attributable to common stockholders $5.64 million versus $7.23 million .Expects that current cash resources will be sufficient to meet operating requirements into 2018.  Full Article